Shots:

• Sarepta exercises its option to acquire Myonexus Therapeutics- in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E- LGMD2D- LGMD2B- LGMD2L & LGMD2C
• In May-2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD- paying $60M upfront & milestones- gaining excsluive option to acquire Myngonexus  
• LGMD2E- LGMD2D- LGMD2B- LGMD2L & LGMD2C are gene therapy programs targeted for MYO-101 (P-I/II)- MYO-102 (P-I/II)- MYO-201 (P-I)- MYO-301 & MYO-103 respectively

Ref: Sarepta Therapeutics | Image: Twitter